Review article: Enzyme supplementation in cystic fibrosis, chronic pancreatitis, pancreatic and periampullary cancer

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue SUPPL. 1, 2010, Pages 1-25

  Imrie, C W ^a   Connett, G ^b   Hall, R I ^c   Charnley, R M ^d  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL DERBY HOSPITAL   (United Kingdom)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; KREON; NUTRIZYM 10; PANCREAS ENZYME; PANCREAS HL; PANCREATIN; PROTEINASE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELIAC DISEASE; CHRONIC PANCREATITIS; CLINICAL FEATURE; CYSTIC FIBROSIS; DRUG EFFICACY; ENTERIC COATED TABLET; ENZYME DENATURATION; ENZYME THERAPY; FAT CONTENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALABSORPTION; PANCREAS CANCER; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATICODUODENECTOMY; PEARSON SYNDROME; PRIORITY JOURNAL; PROTEIN DENATURATION; REVIEW; SHWACHMAN SYNDROME; STEATORRHEA; STOMACH ACID SECRETION; TABLET FORMULATION; VATER PAPILLA CARCINOMA;

EID: 78549291768     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04437.x     Document Type: Review

References (29)

1. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005; 54(Supp VI): vi1-28.
2. Petersen JM, Forsmark CE. Chronic pancreatitis and maldigestion. Semin Gastrointest Dis 2002; 13: 191-9.
3. Layer P, Gröger G. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. Digestion 1993; 54(Suppl. 2): 10-4.
4. Layer P, Keller J. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. J Clin Gastroenterol 1999; 28: 3-10.
5. Pezzilli R. Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol 2009; 15: 1673-6
6. Abbott Healthcare Products Ltd. Data on file January 2010. Cegedim Strategic Data. Number of patients on Creon.
7. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29: 522-6.
8. Cystic Fibrosis Trust. What is cystic fibrosis? Available at: http://www.cftrus-t.org.uk/aboutcf/whatiscf/[last accessed 11 February 2010].
9. Medical Research Council. Achievements & Impact. Cystic fibrosis. December 2006. Available at: http://www.mrc.ac.uk/Achievementsimpact/ Storiesofimpact/Cysticfibrosis/index.htm [last accessed 29 March 2010].
10. Cancer Research UK. Pancreatic cancer - UK incidence statistics. Available at: http://info.cancerresearchuk.org/cancer stats/types/pancreas/ mortality/index.htm [last accessed 27 January 2010].
11. National Health Service. Treating pancreatic cancer. February 2008. Available at: http://www.nhs.uk/Conditions/Can-cer-of-the-pancreas/Pages/Treat- ment.aspx [last accessed 11 February 2010].
12. Pancreatic Section of the British Society of Gastroenterology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005; 54(Suppl. V): v1-16.
13. Neoptolemos JP, Stocken DD, Friess H, et al.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.
14. Botsios D, Zacharakis E, Lambrou I, et al. Our local experience with the surgical treatment of ampullary cancer. Int Semin Surg Oncol 2005; 2: 16.
15. Robertson JF, Imrie CW, Hole DJ, Carter DC, Blumgart LH. Management of periampullary carcinoma. Br J Surg 1987; 74: 816-9.
16. Berberat PO, Künzli BM, Gulbinas A, et al. An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol 2009; 35: 187-91.
17. Williams JG, Roberts SE, Ali MF, et al. Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut 2007; 56: 1-113.
18. Office for National Statistics. Population estimates. August 2009. Available at: http://www.statistics.gov.uk/cci/nugget. asp?ID=6 [last accessed 29 March 2010].
19. Otsuki M. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-26.
20. Ammann RW, Akovbiantz A, Largiader F, Schueler G. Course and outcome of chronic pancreatitis. Gastroenterology 1984; 86: 820-8.
21. Layer P, Yamamoto H, Kalthoff L, et al. The different courses of early and late onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994; 107: 1481-7.
22. Damerla V, Gotlieb V, Larson H, Saif MW. Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 2008; 6: 393-6.
23. MIMS. The Prescribing Reference for General Practice. London, UK: Haymar-ket Medical Media, June 2009. Available at: http://www.mims.co.uk [last accessed 11 February 2010].
24. DiMagno E. Controversies in the treatment of exocrine pancreatic insufficiency. Digest Dis Sci 1982; 27: 481-4.
25. Layer P, Keller J, Lankisch PG. Pancreatic enzyme replacement therapy. Curr Gastroenterol Rep 2001; 3: 101-8.
26. Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GNJ, van Leeuwen DJ. Placebo-controlled trial of enteric coated pancrea-tin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998; 42: 92-6.
27. Solvay Healthcare Ltd. Summary of Product Characteristics. Creon 10000 Capsules; 27 October 2009. Available at: http://www.medicines.org.uk/emc/ document.aspx?documentid=2068& docType=SPC [last accessed 19 April 2010]
28. Solvay Healthcare Ltd data on file 2002. Letter from The London and Manchester Beth Din and Court of the Chief Rabbi (CR166).
29. Solvay Healthcare Ltd data on file 1996. Letter from The London Central Mosque Trust and Islamic Cultural Centre (CR165).